Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2020

Sergio Barberan-Soler's Biography



Sergio Barberan-Soler, CEO, RealSeq Biosciences

Sergio Barberan-Soler is the CEO at RealSeq Biosciences, Inc. He oversees technology development and innovative products to facilitate non-coding small RNA analysis by Next Generation Sequencing. Dr. Barberan-Soler is involved in numerous product development efforts to allow for more accurate quantification of RNA from diverse samples types. Prior to joining RealSeq Biosciences, Dr. Barberan-Soler was the Director of Sequencing Technologies at Somagenics Inc, before that he was a postdoctoral fellow at the CRG in Barcelona and previously received his PhD in Molecular, Cell and Developmental Biology from the University of California, Santa Cruz.

Sergio Barberan-Soler Image

Highly Sensitive Direct Quantification of cf-microRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)

Tuesday, 18 February 2020 at 09:30

Add to Calendar ▼2020-02-18 09:30:002020-02-18 10:30:00Europe/LondonHighly Sensitive Direct Quantification of cf-microRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)Circulating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Cell-free circulating microRNAs (cf-miRNAs) are promising diagnostic and prognostic biomarkers for cancer and other diseases. cf-miRNAs are highly stable in biofluids and are therefore attractive as potential biomarkers via NGS-based detection compared to circulating DNA and protein markers. However, NGS detection of cf-miRNAs suffers from a high level of incorporation bias when sequencing libraries are prepared using the most widely used commercial kits. SomaGenics RealSeq library prep platform addresses this issue, with proven best-in-class accuracy of detection. The RealSeq platform includes a kit designed to profile miRNAs from biofluids (RealSeq-Biofluids) that typically detects four times as many cf-miRNAs as commercially available technologies. The latest kit in the RealSeq platform is RealSeq-T, the first targeted sequencing approach to detect panels of cf-miRNAs (up to 1,200) directly from plasma, with no organic extraction needed. Nearly 95% of sequenced reads from RealSeq-T libraries mapped to the miRNA panel. With these new capabilities, the RealSeq platform should advance the prospects of cf-miRNAs as clinical biomarkers.


Add to Calendar ▼2020-02-17 00:00:002020-02-18 00:00:00Europe/LondonCirculating Biomarkers World Congress 2020Circulating Biomarkers World Congress 2020 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com